Document is current
Any future updates will be listed below
-
Authors
Li, Tong https://orcid.org/0000-0002-8240-4476
Horsfall, David https://orcid.org/0000-0002-8086-812X
Basurto-Lozada, Daniela https://orcid.org/0000-0003-3943-8424
Roberts, Kenny https://orcid.org/0000-0001-6155-0821
Prete, Martin https://orcid.org/0000-0002-5946-821X
Lawrence, John E. G.
He, Peng https://orcid.org/0000-0002-2457-3554
Tuck, Elisabeth
Moore, Josh https://orcid.org/0000-0003-4028-811X
Yoldas, Aybuke Kupcu
Babalola, Kolawole https://orcid.org/0000-0003-1384-8433
Hartley, Matthew https://orcid.org/0000-0001-6178-2884
Ghazanfar, Shila https://orcid.org/0000-0001-7861-6997
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Haniffa, Muzlifah https://orcid.org/0000-0002-3927-2084
Bayraktar, Omer Ali https://orcid.org/0000-0001-6055-277X
- License Information
-
More Information
Article History
First Online: 19 August 2024
Competing interests
: In the past three years, S.A.T. has consulted for or been a member of scientific advisory boards at Qiagen, Sanofi, GlaxoSmithKline and ForeSite Labs. She is a consultant and equity holder for TransitionBio and EnsoCell. J.M. holds equity in Glencoe Software, which builds products based on OME-NGFF. The remaining authors declare no competing interests.
